Beilstein Arch. 2019, 201975. https://doi.org/10.3762/bxiv.2019.75.v1
Published 23 Jul 2019
In recent years, different studies carried out in experimental diabetes models suggest that zinc oxide nanoparticles (ZnONPs) can be good antidiabetic agents, this evidence was obtained from long-term treatments using repeated doses of zinc oxide nanoparticles. The goal of this work was to evaluate the acute effects during six hours post-administration of ZnONPs on glycemia in healthy and diabetic rats and to compare the effects of oral and intraperitoneal administration. For this study male Wistar rats were used and experimental diabetes was induced by streptozotocin-nicotinamide intraperitoneal administration. At short-term ZnONPs administration induced hyperglycemic response in healthy and diabetic rats, the effect was dose-dependent and administration route. The diabetic rats were more sensitive to ZnONPs effect. In conclusion, this study provides novel information about the acute effects of zinc oxide nanoparticles on the fasting glycemia in experimental diabetes in vivo model and healthy rats, these data are important for its future clinical applications.
Keywords: Zinc oxide nanoparticles, diabetes, hyperglycemic response, zinc, nanomedicine, nanoparticles toxicology.
When a peer-reviewed version of this preprint is available, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:
Ibarra-Leal, J. J.; Yocupicio, L.; Apolinar-Iribe, A.; Díaz-Reval, I.; Parra-Delgado, H.; Limón-Miranda, S.; Sánchez-Pastor, E. A.; Virgen-Ortiz, A. Beilstein Arch. 2019, 201975. doi:10.3762/bxiv.2019.75.v1
|Download RIS (Reference Manager)||Download BIB (BIBTEX)|
© 2019 Ibarra-Leal et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited.
The license is subject to the Beilstein Archives terms and conditions: (https://www.beilstein-archives.org/xiv/terms)